SHIGERU YASUE,BOARD OBSERVER
Mr. Shigeru Yasue is a seasoned investment executive with broad business development and execution experience leading to multiple successful exits.
Shigeru is currently board of Medical Development Support 1 Limited Partnership with over 20 years of VC investment experience with Mitsubishi UFJ Capital.
Shigeru has been involved with multiple successful exits with both Japanese and U.S. companies including Five Prime Therapeutics, Inc.(FPRX), Opko Health ,Inc.(OPK), Affymax,Inc.(AFFY), MacroGenics Inc. (MGNX), KaloBios Pharmaceuticals,Inc (KBIO), iPierian Inc.,(Acquired by Bristol Myers Squibb), Solasia Pharmaceuticals ( Tokyo Stock Exchange, Mothers), SanBio (TSE, Mothers), StemRim (TSE ,Mothers), Modaris (TSE ,Mothers).
Shigeru was previous board member of TMS,Co.,Ltd.,developing a novel acute stroke agent and was acquired by Biogen in June 2021.